SignalCorporate
FTC and seven states seek contempt ruling against Shkreli over pharma ban
FTC and seven states seek contempt ruling against Shkreli over pharma ban.
Context
What happened: The FTC and seven US states filed a motion in New York federal court asking a judge to hold Martin Shkreli in contempt, alleging he violated a lifetime ban on participating in the pharmaceutical industry.
Key numbers: Shkreli is 43. He was released from prison in May 2022. The motion alleges stock trades in at least 60 pharmaceutical companies.
Why it matters: The 2022 release conditions bar him from ownership stakes or business decisions in the industry. Plaintiffs want a contempt ruling over the alleged repeated violations.
Coverage: 9 outlets in 24h
What changed
The FTC and seven US states filed a motion in New York federal court asking a judge to hold Martin Shkreli in contempt, alleging he violated a lifetime ban on participating in the pharmaceutical industry.
Why it matters
The 2022 release conditions bar him from ownership stakes or business decisions in the industry. Plaintiffs want a contempt ruling over the alleged repeated violations.